Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity
Uloženo v:
| Název: | Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity |
|---|---|
| Autoři: | Cassidy, Adrian, Mossman, Sally P., Olivieri, Antonio, De Ridder, Marc, Leroux-Roels, Geert |
| Zdroj: | Expert review of vaccines, 10 (12 |
| Informace o vydavateli: | Informa UK Limited, 2011. |
| Rok vydání: | 2011 |
| Témata: | 0301 basic medicine, Hepatitis B virus, Genotype, genotype, effectiveness, Pharmacologie, Hepatitis B virus -- genetics -- immunology -- pathogenicity, 03 medical and health sciences, recombinant vaccine, vaccine, Immunologie, Hepatitis B Vaccines -- administration & dosage -- genetics -- immunology, Humans, Hepatitis B Vaccines, Hepatitis B Antibodies, Hepatitis B -- blood -- immunology -- prevention & control -- virology, Vaccines, Vaccines, Synthetic, 0303 health sciences, Synthetic -- administration & dosage -- genetics -- immunology, Vaccination, Hepatitis B Antibodies -- blood -- immunology, Biologie moléculaire, Vaccines, Synthetic -- administration & dosage -- genetics -- immunology, Genetic Variation, Hepatitis B, 3. Good health, hepatitis B |
| Popis: | Recombinant hepatitis B vaccines are of the A2 genotype; one of ten known genotypes whose distribution varies globally. Reports of rare HBV infections in blood donors with an imbalance of non-A2 genotype HBV in vaccinated subjects have raised questions about the cross-protection afforded by HBV-A2 vaccines. Infections in HBV vaccinees were asymptomatic and transient, indicating that vaccination prevented clinical disease. Preclinical data demonstrate cross-reactivity and cross-protection by A2 vaccines against non-A2 HBV genotypes. Substantial improvements in HBV control have been demonstrated in countries with diverse genotype distribution that have introduced universal childhood HBV vaccination programs. Available data show that current HBV-A2 vaccines are highly effective in preventing infections and clinical disease caused by all known HBV genotypes. |
| Druh dokumentu: | Article |
| Popis souboru: | 2 full-text file(s): application/pdf; application/octet-stream |
| Jazyk: | English |
| ISSN: | 1744-8395 1476-0584 |
| DOI: | 10.1586/erv.11.151 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/22085174 https://biblio.ugent.be/publication/2066042 https://www.tandfonline.com/doi/full/10.1586/erv.11.151 https://pubmed.ncbi.nlm.nih.gov/22085174/ https://core.ac.uk/display/77565734 https://europepmc.org/article/MED/22085174 http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/196369 |
| Přístupové číslo: | edsair.doi.dedup.....a1625fb5affd36509b9d002b540a11f4 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Recombinant hepatitis B vaccines are of the A2 genotype; one of ten known genotypes whose distribution varies globally. Reports of rare HBV infections in blood donors with an imbalance of non-A2 genotype HBV in vaccinated subjects have raised questions about the cross-protection afforded by HBV-A2 vaccines. Infections in HBV vaccinees were asymptomatic and transient, indicating that vaccination prevented clinical disease. Preclinical data demonstrate cross-reactivity and cross-protection by A2 vaccines against non-A2 HBV genotypes. Substantial improvements in HBV control have been demonstrated in countries with diverse genotype distribution that have introduced universal childhood HBV vaccination programs. Available data show that current HBV-A2 vaccines are highly effective in preventing infections and clinical disease caused by all known HBV genotypes. |
|---|---|
| ISSN: | 17448395 14760584 |
| DOI: | 10.1586/erv.11.151 |